Irtisha Singh

Irtisha Singh

Auto-generated profile, based on publicly available information

Irtisha Singh

Department of Biomedical Engineering, College of Engineering, Texas A&M University, College Station, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2020 in Nature Reviews Materials
Verified
Journal Article
Closed access
PDF file
AGAkhilesh K. Gaharwar
Akhilesh K. Gaharwar
ISIrtisha Singh
Irtisha Singh
Ali  KhademhosseiniAli Khademhosseini
Ali Khademhosseini

27 August 2018 in Nature
Verified
Journal Article
Closed access
PDF file
SLShih-Han Lee
Shih-Han Lee
ISIrtisha Singh
Irtisha Singh
STSarah Tisdale
Sarah Tisdale
OAOmar Abdel-Wahab
Omar Abdel-Wahab
CLChristina S. Leslie
Christina S. Leslie
CMChristine Mayr
Christine Mayr

30 April 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
ISIrtisha Singh
Irtisha Singh
SLShih-Han Lee
Shih-Han Lee
ASAdam S. Sperling
Adam S. Sperling
MSMehmet K. Samur
Mehmet K. Samur
YTYu-Tzu Tai
Yu-Tzu Tai
CLChristina S. Leslie
Christina S. Leslie
Alternative cleavage and polyadenylation (ApA) is known to alter untranslated region (3ʹUTR) length but can also recognize intronic polyadenylation (IpA) signals to generate transcripts that lose part or all of the coding region. We analyzed 46 3ʹ-seq and RNA-seq profiles from normal human tissues, primary immune cells, and multiple myeloma (MM) samples and created an atlas of 4927 high-confidence IpA events represented in these cell types. IpA isoforms are widely expressed in immune cells, differentially used during B-cell development or in different cellular environments, and can generate truncated proteins lacking C-terminal functional domains. This can mimic ectodomain shedding through loss of transmembrane domains or alter the binding specificity of proteins with DNA-binding or protein–protein interaction domains. MM cells display a striking loss of IpA isoforms expressed in plasma cells, associated with shorter progression-free survival and impacting key genes in MM biology and response to lenalidomide.

24 February 2020 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
DCDavid Chimene
David Chimene
LMLogan Miller
Logan Miller
LCLauren M. Cross
Lauren M. Cross
MJManish K. Jaiswal
Manish K. Jaiswal
ISIrtisha Singh
Irtisha Singh
AGAkhilesh K. Gaharwar
Akhilesh K. Gaharwar

11 April 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JCJames K. Carrow
James K. Carrow
LCLauren M. Cross
Lauren M. Cross
RRRobert W. Reese
Robert W. Reese
MJManish K. Jaiswal
Manish K. Jaiswal
CGCarl A. Gregory
Carl A. Gregory
AGAkhilesh K. Gaharwar
Akhilesh K. Gaharwar
Significance: We demonstrate the use of next-generation sequencing technology (RNA-seq) to understand the effect of a two-dimensional nanomaterial on human stem cells at the whole-transcriptome level. Our results identify more than 4,000 genes that are significantly affected, and several biophysical and biochemical pathways are triggered by nanoparticle treatment. We expect that this systematic approach to understand widespread changes in gene expression due to nanomaterial exposure is key to develop new bioactive materials for biomedical applications.

4 April 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SMStephen C. Mack
Stephen C. Mack
ISIrtisha Singh
Irtisha Singh
XWXiuxing Wang
Xiuxing Wang
RHRachel Hirsch
Rachel Hirsch
QWQuilian Wu
Quilian Wu
JRJeremy N. Rich
Jeremy N. Rich
Glioblastoma is an incurable brain cancer characterized by high genetic and pathological heterogeneity. Here, we mapped active chromatin landscapes with gene expression, whole exomes, copy number profiles, and DNA methylomes across 44 patient-derived glioblastoma stem cells (GSCs), 50 primary tumors, and 10 neural stem cells (NSCs) to identify essential super-enhancer (SE)–associated genes and the core transcription factors that establish SEs and maintain GSC identity. GSCs segregate into two groups dominated by distinct enhancer profiles and unique developmental core transcription factor regulatory programs. Group-specific transcription factors enforce GSC identity; they exhibit higher activity in glioblastomas versus NSCs, are associated with poor clinical outcomes, and are required for glioblastoma growth in vivo. Although transcription factors are commonly considered undruggable, group-specific enhancer regulation of the MAPK/ERK pathway predicts sensitivity to MEK inhibition. These data demonstrate that transcriptional identity can be leveraged to identify novel dependencies and therapeutic approaches.